1 SA Pharmacy, Flinders Medical Centre, Bedford Park, South Australia, Australia
2 College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia
3 Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia
4 Department of Anaesthetics, Flinders Medical Centre, Bedford Park, South Australia, Australia
Correspondence to: Greg Roberts — Greg.Roberts2@sa.gov.au
Cite as: Roberts G, Moore A, Scarfo NL, Geekie M, Figueroa K, Hall C, Koerber J. A retrospective analysis of analgesia prescribing in the 24 hours before discharge for spinal surgeries and associated discharge analgesia prescribing. South Aust J Med. 2026;1(2):e0014.
DOI: 10.66861/NLZM7702 Open access · CC BY 4.0
Submitted 8 Jun 2026 Accepted 23 Aug 2026 Published 1 Sep 2026
Abstract
Background: Spinal surgery is associated with substantial post-operative analgesia needs. Opioid-sparing therapy with non-steroidal anti-inflammatories (NSAIDs) and atypical opioids (tramadol, tapentadol) offer an option before the use of conventional opioids. We assessed the uptake of NSAID and atypical opioid use and their association with conventional opioid prescribing.
Methods: Those undergoing spinal surgery at a tertiary hospital were retrospectively assessed for NSAID and atypical opioid use in the 24 hours before discharge. The relationship with the discharge prescribing of analgesia was analysed.
Results: Of 147 eligible subjects, only 28% of NSAID-eligible and 51% of atypical opioid-eligible subjects received these in the 24 hours before discharge. Multiple linear regressions indicate that atypical opioid use was independently associated with both decreased conventional opioid use in the 24 hours before discharge (p = 0.0089) and decreased conventional opioid prescribing at discharge (p = 0.0054), whereas NSAID use was not. There was poor correlation between conventional opioid use in the 24 hours before discharge and the amount prescribed at discharge (r2 = 0.066, p = 0.0020). Of the 40 who did not require conventional opioid analgesia in the 24 hours before discharge, 19 were prescribed opioids at discharge. Conversely, of the 41 patients who required > 20 mg oxycodone in the 24 hours before discharge, 19 received no conventional opioid at discharge.
Conclusion: Inpatient atypical opioid use was associated with decreased conventional opioid use in the 24 hours before discharge and at discharge. Choice and quantity of discharge prescribing was inconsistent with inpatient use in the 24 hours before discharge. NSAIDs and atypical opioids were largely underused. There is significant scope for improved prescribing of post-operative opioid-sparing analgesia in those undergoing spinal surgery.
Keywords: postoperative pain · analgesia · opioids · NSAID
Editor’s preface
Atypical opioids measurably reduced conventional opioid use after spinal surgery — NSAIDs, oddly, did not. More striking still: what patients actually needed as inpatients bore little relationship to what they were sent home with. A study about the gap between what we observe and what we prescribe.
— The Editors
Introduction
Opioids are effective for short-term acute pain management in the immediate post-operative period, making them an appealing choice for prescribers. Surgeons are the second leading prescribers of opioids.1 Those undergoing surgery are nearly four times more likely to receive conventional opioids on discharge than other patients.2 Consequently, even minor surgeries can serve as an initial event for opioid-naïve patients to become persistent opioid users. While adjuvant opioid-sparing agents are encouraged, the decision to prescribe them alongside or instead of conventional opioids during admission or at discharge depends largely on prescriber preference and healthcare culture. The extent of the use of opioid-sparing options and atypical opioids in place of conventional opioids within the post-operative analgesia setting remain unclear.
Australian guidance on non-complex post-operative analgesia recommends post-operative use of paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) to reduce the dose of opioid analgesics.3,4 During short-term post-operative use, opioids are commonly associated with sedation, constipation and respiratory depression; long-term use is associated with an increased risk of tolerance, misuse and addiction.5,6 NSAIDs work synergistically with opioids. However, in the peri-operative setting, prescribers can be hesitant to use NSAIDs, even in the short-term. This might be attributed to fear of adverse effects and haemorrhagic complications.7 Tramadol and tapentadol (atypical opioids) are more recently available options and are regarded as having more favourable adverse effect profiles than conventional opioids.8
Spinal surgery is associated with substantial post-operative analgesia needs. Many patients require regular pre-operative analgesia to manage pain while awaiting surgery. Guidelines specifically support the use of NSAIDs to treat post-operative pain for spinal surgeries, unless contra-indicated. Opioid use is a rescue therapy.9
National guidance recommends aligning discharge analgesia with the analgesia needs of the 24 hours before discharge.10 In practice, junior inexperienced medical staff are responsible for discharge analgesia prescribing and receive little or no local guidance. We expected that opioid-sparing strategies would be employed and discharge prescribing would reflect patient use in the 24-hours before discharge. In line with these expectations, we assessed:
- the extent of adjunctive analgesia (NSAIDs and atypical opioids) use in the 24 hours before discharge
- the relationship between use of adjunctive analgesia in the 24 hours before discharge, concurrent inpatient conventional opioid analgesia use and opioid discharge prescribing.
Methods
This retrospective observational cohort study evaluated patients who underwent spinal surgery between April 2021 and November 2022 at a 700-bed tertiary hospital. Exclusions were post-operative lengths of stay (LOS) of less than one day or more than five days, the use of intra-operative spinal morphine, and the patient being younger than 18 years age, pregnant or being discharged to a destination other than home.
The cohort was identified from hospital casemix outputs using internationally standardised procedure codes according to the Master International Classification of Diseases-10 Procedure Coding. Procedures were nominally categorised into spinal decompression (including those listed as having undergone decompression of spinal nerve roots, decompression of lumbar spinal canal at one level, decompression of canal at two or more levels, decompression of thoracic spinal cord at one level, decompression of lumbar spinal canal at one level and decompression of cervical spinal cord at two or more levels ), spinal fusion (including posterior column spinal fusion at one level, posterior column spinal fusion at two or more levels, anterior column spinal fusion at one level and anterior column spinal fusion at two or more levels) and discectomy (discectomy at one level). Analgesia use in the 24 hours before discharge and discharge medication prescriptions were extracted from the electronic medical records on an individual patient basis. Data were managed using REDCap electronic data capture tools hosted at Yale University.11,12
Analgesia-specific data included the use of regular pre-admission analgesia, intra-operative analgesia, analgesia use in the 24 hours before discharge, and analgesia prescribed at discharge. Conventional opioid intake in the 24 hours before discharge was converted to an oral oxycodone equivalent, in accordance with the World Health Organisation’s defined daily dose index.13 Tramadol and tapentadol (atypical opioids) were categorised separately from conventional opioids, unless otherwise stated. The number of days of conventional opioid prescribed at discharge was calculated as the quantity prescribed divided by the conventional opioid use in the 24 hours before discharge.
Demographic data, comorbidities, known adverse drug reactions, and pre- and post-operative renal function were collected. Patient eligibility for short-term NSAID use was assessed in accordance with relevant comorbidities, concurrent medications, renal function, intra-operative blood loss greater than 500 mL and known adverse drug reactions. Defined contra-indications to NSAIDs included a known allergy, congestive heart failure, NSAID-sensitive asthma, a history of gastrointestinal bleeding, inflammatory bowel disease, peptic ulcer disease, an organ transplant, an active acute kidney injury, concurrent use of antiplatelets and anticoagulants’, and concurrent use of ACE inhibitors or angiotensin receptor blockers with furosemide. Patient eligibility for atypical opioids was assessed in accordance with the listed adverse drug reactions for each patient. Analgesia use was also assessed for the three spinal surgery types (spinal decompression, spinal fusion and discectomy), as well as the requirement for regular pre-admission analgesia.
Regular pre-admission use of analgesia was defined as regular use of NSAIDs, atypical opioids, gabapentinoids or conventional opioids, but not paracetamol. Tramadol was the preferred in-hospital atypical opioid. Further, tapentadol requires special approval for inpatient use.
This study was approved by the Southern Adelaide Local Health Network Office of Research (reference number 002.23 and LNR reference number LNR/23/SAC/002).
Statistics
A student t test was used to compare the continuous data, a chi-squared test for the dichotomous data, and a one-way analysis of variance for the means across more than two groups. Any p values less than 0.05 were considered significant. The influence of regular pre-admission use of conventional opioids, age, and atypical opioid and NSAID use in the 24 hours before discharge were employed as variables in multiple linear regression models to determine the relationship with conventional opioid use in the 24 hours before discharge. This model was also used to assess the relationship with the amount of conventional opioid prescribed at discharge.
Results
We identified 147 eligible patients over the two-year retrospective study period, of whom 32 (22%) underwent discectomy, 39 (27%) spinal fusion and 76 (51.7%) spinal decompression (see Table 1). Within the cohort, 58% were male, the mean age was 58 years, and the median (Inpatient Quality Reporting) LOS was 2.5 (2.0–3.6) days. There were 79 patients (54.7%) who required regular analgesia before admission for spinal surgery: 25 (28%) on NSAIDs, 55 (70%) on gabapentinoids (51 pregabalin, four gabapentin), 19 (24%) on atypical opioids (12 tramadol, seven tapentadol) and 21 (27%) on conventional opioids. Intra-operative parecoxib was used in 67 patients (45.6%). Only 10 of these patients subsequently received further post-operative NSAIDs.
Both paracetamol and conventional opioid analgesia were prescribed in more than 95% of all patients (see Figure 1A). After applying the NSAID contra-indication criteria and known adverse drug reactions, 76 patients (51.7%) remained eligible for NSAID use. Of these, 58 (76%) were not prescribed inpatient NSAIDs and relied on a combination of paracetamol and a conventional opioid, except one patient, who was prescribed tramadol.
Analgesia use in the 24 hours before discharge
In the 24 hours before discharge, only 10 of the 76 (13%) NSAID-eligible patients received NSAIDs. Atypical opioids were prescribed for 71 (50.7%) of the 140 that were eligible. Overall, 90 of 147 (61.2%) patients were prescribed either atypical opioids or NSAIDS. Of the 57 remaining, 47 (82%) patients received conventional opioid analgesia with no concurrent NSAID or atypical opioid prescribed.
Multiple linear regression modelling indicated that the amount of conventional opioid used in the 24 hours before discharge was lower with concurrent atypical opioid use (p = 0.0089). In addition, with increasing age (p < 0.0001), it was higher in those with regular pre-admission use of conventional opioids (p < 0.0001), and not associated with concurrent NSAID use (p = 0.67). The model resulted in an R value of 0.52 (R2 = 0.27, p < 0.0001), suggesting that 27% of the variation in opioid use could be explained by the variables in the model.
LOS, surgery type, use of intra-operative parecoxib and gender were not significantly associated with outcomes when individually added to the model, nor did they influence the relationship between other variables and the outcome.
The amount of opioid used in the 24 hours before discharge varied across the three types of surgery (see Figure 1B). Those requiring regular analgesia before surgery were more likely to use opioid analgesia in the 24 hours before discharge (80% v. 62%, p = 0.026; see Figure 1C).
Discharge prescribing
Conventional opioids were prescribed at discharge for 93 of 147 (63.3%) patients. These consisted almost exclusively of oxycodone: 89 of 93 (95.7%). Five of those prescribed oxycodone also received concurrent atypical opioids, and a further seven (4.7%) received an atypical opioid at discharge with no conventional opioid.
In adjusted modelling, the amount of discharge opioid prescribed was lower in those inpatients who were prescribed atypical opioids in the 24 hours before discharge (p = 0.0054), was increased in those taking regular conventional opioids before admission (p = 0.0017), and was not influenced by the inpatient prescription of NSAIDs (p = 0.20) or age (p = 0.91; see Table 2). This model yielded an R value of 0.34 (R2 = 0.12, p < 0.001), suggesting that 12% of the variation in the discharge opioid could be explained by the variables in the model.
The percentage of patients prescribed opioids at discharge generally increased in line with the opioid use in the 24 hours before discharge (see Figure 2A), as did the opioid quantity prescribed at discharge (Figure 2B).
From the opioid use in the 24 hours before discharge, 30 of 147 patients (20.4%) received discharge opioids despite having used 10 mg or less in the 24 hours before discharge. Conversely, of the 59 patients using more than 20 mg in the 24 hours before discharge, 20 received no opioid analgesia at discharge.
Discussion
The use of atypical opioids, but not NSAIDs, in the 24 hours before discharge was independently associated with decreased conventional opioid use during this period and with decreased conventional opioid discharge prescribing. There was poor NSAID uptake among eligible patients in the 24 hours before discharge, restricting the ability to discern a clear impact on conventional opioid use. There remains considerable scope for increased use of NSAIDs and atypical opioids in place of conventional opioids in the 24 hours before discharge for this cohort. The opportunity to prescribe these analgesics in this period as an alternative to conventional opioids was available to 51.7% of the total cohort, but not well used.
Discharge opioid prescribing did not reflect the analgesic requirements established in the 24 hours preceding discharge. Approximately half of the patients who did not require opioids in the 24 hours before discharge received opioids at discharge. Conversely, approximately half of those who required more than 20 mg of oxycodone in the 24 hours before discharge did not receive discharge opioids or atypical opioids. In total, 25.8% of all patients received excessive opioids or potentially insufficient opioids at discharge.
Patients who had regular analgesic use before admission had significantly higher opioid requirements in the 24 hours before discharge than those without this.
Prescriber uncertainty about the clinical safety profile of short-term NSAID use has been clarified more recently by the release of the Resources for Opioid Stewardship Implementation (ROSI) guidelines for post-operative celecoxib14; this will encourage prescriber confidence in using NSAIDs for post-operative pain. The contra-indication criteria applied in this study were more restrictive than those specified in the most recent ROSI guidelines. As a result, this study likely underestimated the proportion of patients who could appropriately receive adjunctive NSAIDs under current national guidance.
Atypical opioids were also underused in this cohort, despite them being formally recommended in the local hospital guidelines. Tapentadol, in particular, appears to offer advantages over conventional opioids in regard to adverse effect profiles, addiction potential and risk of diversion to non-medical use.15 Tramadol and tapentadol are commonly classified alongside conventional opioids despite their atypical mechanism of action. This conflation may discourage a stepwise approach to analgesia, one in which atypical opioids are trialled before conventional opioids or combination therapy is initiated. We chose to assess atypical opioid use separately from that of conventional opioids given that they are an alternative to conventional opioids. This approach is not well reflected in conventional guidelines, which generally classify tramadol and tapentadol with other opioids.
The study was observational and subject to limitations. We did not assess patterns of inpatient gabapentinoid. While gabapentinoids have some efficacy for neuropathic pain, they are not formally recommended in multimodal post-operative analgesia regimens. There is, however, some evidence of post-operative pain attenuation if used in the post-operative period.16 We did not assess response to analgesia. Some patients may have had sufficient conventional opioid analgesia at home and not required a prescription at discharge. While we adjusted for recognised variables, other non-clinical factors contribute to opioid use. While continuing analgesia was needed in some, it may have been at reduced doses. We only assessed those in hospital for up to four days after surgery. Those with a greater LOS may have experienced post-operative complications with altered post-operative analgesia needs. The smaller numbers available in some subgroup analyses, especially those receiving NSAIDs, limited statistical power.
There remains considerable opportunity to better use post-operative NSAID and atypical opioid therapy before the use of conventional opioids in the latter stages of admission and at discharge. Clinical decision support tools could assist prescribers in assessing short-term NSAID eligibility at the point of discharge. Systematic quantification of analgesia use in the 24 hours before discharge would further enable more informed and individualised discharge prescribing.
| Procedure | Preadmission analgesia status | |||||
|---|---|---|---|---|---|---|
| All | Discectomy | Spinal fusion | Decompression | No regular analgesia | Regular analgesia | |
| N | 147 | 32 | 39 | 76 | 68 | 79 |
| Male sex | 85 (57.8) | 15 (47) | 25 (64) | 44 (59) | 38 (56) | 47 (59) |
| Age (y) (mean±SD) | 58±16 | 45±13 | 56±14 | 64±14 | 57±16 | 59±16 |
| Hospital LOS (days) median (IQR) | 2.5 (2.0–3.6) | 1.9 (1.4–2.6)a | 3.2 (2.2–3.9) | 2.8 (2.2–3.8) | 2.6 (2.3–3.7) | 2.3 (1.4–3.3) |
| Post-op LOS (days) median (IQR) | 2.1 (1.3–3.3) | 1.2 (1.1–2.0)a | 2.3 (2.0–3.2) | 2.6 (1.9–3.3) | 2.2 (1.7–3.2) | 2.1 (1.3–3.2) |
| Regular preadmission analgesia | ||||||
| Opioids | 21 (14.0) | 4 (13) | 4 (10) | 13 (17) | 0 | 21 (26) |
| Tramadol or tapentadol | 19 (12.9) | 5 (16) | 5 (13) | 9 (12) | 0 | 19 (24) |
| NSAIDs | 25 (17.0) | 6 (19) | 6 (15) | 13 (17) | 0 | 25 (32) |
| Gabapentinoids | 55 (37.4) | 14 (44) | 12 (31) | 29 (38) | 0 | 55 (70) |
| More than one analgesic | 31 (21.1) | 8 (25) | 6 (15) | 17 (22) | 0 | 31 (39) |
| Known ADRs | ||||||
| NSAIDs | 12 (8) | 3 (9) | 2 (5) | 7 (9) | 5 (7) | 7 (9) |
| Opioids | 16 (11) | 5 (16) | 2 (5) | 9 (12) | 8 (12) | 8 (10) |
| Tramadol/tapentadol | 7 (5) | 1 (3) | 0 (0) | 6 (8) | 7 (10)b | 0 (0) |
| Comorbidities | ||||||
| Heart failure | 3 (2) | 0 (0) | 1 (3) | 2 (3) | 0 (0) | 3 (6) |
| Atrial fibrillation | 6 (4) | 0 (0) | 2 (5) | 4 (5) | 3 (4) | 3 (4) |
| History of gastrointestinal bleed | 6 (4) | 2 (6) | 0 (0) | 4 (5) | 0 (0) | 0 |
| Diverticulitis | 7 (5) | 1 (3) | 2 (5) | 4 (5) | 4 (6) | 3 (4) |
| Bariatric surgery | 2 (1) | 1 (3) | 0 (0) | 1 (1) | 1 (1) | 1 (1) |
| NSAID contraindications | 75 (51.0) | 14 (44) | 15 (38) | 46 (61) | 33 (49) | 42 (51) |
| Relevant concurrent medications | ||||||
| ACE I/ARB | 60 (41) | 10 (31) | 8 (21) | 42 (55) | 26 (38) | 34 (43) |
| Furosemide | 4 (3) | 1 (3) | 1 (3) | 2 (3) | 2 (3) | 2 () |
| Anticoagulant | 7 (5) | 0 (0) | 4 (10) | 3 (4) | 3 (4) | 4 (5) |
| Antiplatelet | 21 (14) | 1 (3) | 2 (5) | 18 (24) | 9 (13) | 12 (15) |
No subjects had uncontrolled hypertension, active GI bleeding or a history of NSAID-related asthma, inflammatory bowel disease or organ transplant.
a p < 0.01 for discectomy versus spinal fusion and versus decompression (one-way ANOVA).
b p < 0.05 for opioid naïve versus regular analgesia.
N (%) unless otherwise stated.
| Coefficient | SE | t statistic | Standard coefficient | p value | |
|---|---|---|---|---|---|
| Relationship with conventional opioid use 24 hours before discharge | |||||
| Atypical opioid used | −12.2 | 4.6 | −2.7 | −0.191 | 0.0089 |
| NSAID used | −2.5 | 5.9 | −0.43 | −0.032 | 0.67 |
| Age | −0.58 | 0.13 | −4.39 | −0.32 | <0.0001 |
| Preadmission opioid use | 29.1 | 5.86 | 4.96 | 0.36 | <0.0001 |
| Relationship with discharge prescribing of conventional opioid | |||||
| Atypical opioid used | −4.02 | 1.42 | −2.82 | −0.22 | 0.0054 |
| NSAID used | 2.32 | 1.81 | 1.28 | 0.10 | 0.20 |
| Age | 0.0048 | 0.041 | 0.16 | 0.0093 | 0.91 |
| Preadmission opioid use | 6.20 | 1.94 | 3.21 | 0.26 | 0.0017 |
Figure 1. Prescribing in 24 hours before discharge



Figure 2. Relationship between conventional opioid use (oxycodone equivalent) in 24 hours before discharge



References
- Levy B, Paulozzi L, Mack KA, Jones CM. Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007–2012. Am J Prev Med. 2015;49(3):409–13.
- Brat GA, Agniel D, Beam A, Yorkgitis B, Bicket M, Homer M, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. Br Med J 2018;360:j5790.
- Australian and New Zealand College of Anaesthetists. PS41(G): Position statement on acute pain management. 2023. [Internet, cited 2026 Aug 26] Available from: https://www.anzca.edu.au/getattachment/558316c5-ea93-457c-b51f-d57556b0ffa7/PS41-Guideline-on-acute-pain-management
- Australian Commission on Safety and Quality in Health Care. Opioid analgesic stewardship in acute pain clinical care standard: Acute care edition [Internet]. 2020. [cited 2026 Aug 26] Available from: https://www.safetyandquality.gov.au/standards/clinical-care-standards/opioid-analgesic-stewardship-acute-pain-clinical-care-standard
- Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription opioid analgesics commonly unused after surgery: A systematic review. JAMA Surg. 2017;152(11):1066–71.
- Waljee JF, Li L, Brummett CM, Englesbe MJ. Iatrogenic opioid dependence in the United States: Are surgeons the gatekeepers? Ann Surg. 2017;265(4):728–30.
- Chang RW, Tompkins DM, Cohn SM. Are NSAIDs safe? Assessing the risk–benefit profile of nonsteroidal anti-Inflammatory drug use in postoperative pain management. Am Surg. 2020;87(6):872–9.
- Roulet L, Rollason V, Desmeulles J, Piguet V. Tapentadol versus tramadol: A narrative and comparative review of their pharmacological, efficacy and safety profiles in adult patients. Drugs. 2021;81:1257–1272. https://doi.org/10.1007/s40265-021-01515-z
- European Society of Regional Anaesthesia and Pin Therapy. Prospect [Internet]. 2020 [cited 2024 May 8]. Available from: https://esraeurope.org/prospect/procedures/complex-spine-surgery-2020/abbreviations-17/
- Schug SA, Palmer GM, Scott DA, Alcock M, Halliwell R, Mott JF. Acute pain management: Scientific evidence. 5th ed. Melbourne: ANZCA & FPM; 2020.
- Harris PA, Taylor R Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377–81.
- Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software partners. J Biomed Inform. 2019 Jul;95:103208. doi:10.1016/j.jbi.2019.103208
- World Health Organisation. WHO collaborating centre for drug statistics methodology [Internet]. 2023 [cited 2024 January 22]. https://www.who.int/tools/atc-ddd-toolkit/methodology.
- Australia and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Guidelines for the use and prescribing of celecoxib [Internet]. 2024 [cited 2024 May 8]. Available from: https://www.anzca.edu.au/resources/rosi/rosi_celecoxib_protocol.pdf
- Wang X, Narayan SW, Penm J, Patanwala AE. Efficacy and safety of tapentadol immediate release for acute pain: A systematic review and meta-analysis. Clin J Pain. 2020 May;36(5):399–409. doi:10.1097/AJP.0000000000000809
- Khurana G, Jindal P, Sharma JP, Bansal KK. Postoperative pain and long-term functional outcome after administration of gabapentin and pregabalin in patients undergoing spinal surgery. Spine. 2014;39:E363–8. doi:10.1097/BRS.0000000000000185
Acknowledgements: The authors would like to acknowledge the work of reviewers Sally Marotti and Dr Cher-Run Chong.
Funding statement: No funding was received for this work.
Conflict of interest statement: The authors declare no conflicts of interest.
Ethics approval: Not applicable
Data availability statement: Not applicable
Use of AI tools: Generative artificial intelligence tools were not used in the preparation of this manuscript, including for drafting text, data analysis, figure generation, or peer-reviewed responses.